Equities researchers at StockNews.com initiated coverage on shares of 22nd Century Group (NASDAQ:XXII – Get Free Report) in a research report issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.
22nd Century Group Stock Up 10.0 %
22nd Century Group stock opened at $0.18 on Wednesday. The business’s 50-day simple moving average is $0.45 and its 200 day simple moving average is $3.37. The stock has a market cap of $1.52 million, a price-to-earnings ratio of 0.00 and a beta of 1.41. 22nd Century Group has a 12-month low of $0.15 and a 12-month high of $12.32.
22nd Century Group (NASDAQ:XXII – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. The firm had revenue of $7.95 million during the quarter. 22nd Century Group had a negative net margin of 275.12% and a negative return on equity of 380.39%.
Hedge Funds Weigh In On 22nd Century Group
About 22nd Century Group
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Read More
- Five stocks we like better than 22nd Century Group
- What is the Euro STOXX 50 Index?
- When Is the Best Time to Invest in Mutual Funds?
- What is the Nikkei 225 index?
- Is NVIDIA Stock in a Correction or Consolidation?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.